The Association of Hydration Status with Physical Signs, Symptoms and Survival in Advanced Cancer-The Use of Bioelectrical Impedance Vector Analysis (BIVA) Technology to Evaluate Fluid Volume in Palliative Care: An Observational Study.
BACKGROUND
Hydration in advanced cancer is a controversial area; however, current hydration assessments methods are poorly developed. Bioelectrical impedance vector analysis (BIVA) is an accurate hydration tool; however its application in advanced cancer has not been explored. This study used BIVA to evaluate hydration status in advanced cancer to examine the association of fluid status with symptoms, physical signs, renal biochemical measures and survival.


METHODS
An observational study of 90 adults with advanced cancer receiving care in a UK specialist palliative care inpatient unit was conducted. Hydration status was assessed using BIVA in addition to assessments of symptoms, physical signs, performance status, renal biochemical measures, oral fluid intake and medications. The association of clinical variables with hydration was evaluated using regression analysis. A survival analysis was conducted to examine the influence of hydration status and renal failure.


RESULTS
The hydration status of participants was normal in 43 (47.8%), 'more hydrated' in 37 (41.1%) and 'less hydrated' in 10 (11.1%). Lower hydration was associated with increased symptom intensity (Beta = -0.29, p = 0.04) and higher scores for physical signs associated with dehydration (Beta = 10.94, p = 0.02). Higher hydration was associated with oedema (Beta = 2.55, p<0.001). Median survival was statistically significantly shorter in 'less hydrated' patients (44 vs. 68 days; p = 0.049) and in pre-renal failure (44 vs. 100 days; p = 0.003).


CONCLUSIONS
In advanced cancer, hydration status was associated with clinical signs and symptoms. Hydration status and pre-renal failure were independent predictors of survival. Further studies can establish the utility of BIVA as a standardised hydration assessment tool and explore its potential research application, in order to inform the clinical management of fluid balance in patients with advanced cancer.
Marie Curie Palliative Care Institute Liverpool (MCPCIL), University of Liverpool, Liverpool, United Kingdom.
Amara Callistus
http://orcid.org/0000-0003-0014-3741
AC
Nwosu
Marie Curie Palliative Care Institute Liverpool (MCPCIL), University of Liverpool, Liverpool, United Kingdom.
Catriona R
CR
Mayland
Marie Curie Palliative Care Institute Liverpool (MCPCIL), University of Liverpool, Liverpool, United Kingdom.
Stephen
S
Mason
Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, United Kingdom.
Trevor F
TF
Cox
School of Physiological Sciences, University of Liverpool, Liverpool, United Kingdom.
Andrea
A
Varro
Marie Curie Palliative Care Institute Liverpool (MCPCIL), University of Liverpool, Liverpool, United Kingdom.
John
J
Ellershaw
Am J Clin Nutr. 1986 Sep;44(3):417-24
3529918
J Clin Oncol. 2013 Jan 1;31(1):111-8
23169523
N Engl J Med. 1984 Sep 20;311(12):753-9
6472364
Nutrition. 2008 Jun;24(6):569-74
18455657
Clin Interv Aging. 2009;4:225-33
19554093
Nutrition. 2003 Jun;19(6):510-4
12781850
Lyon Med. 1962 Jul 15;94:107-18
13920843
Psychosomatics. 1982 Nov;23(11):1125-7, 1130-1, 1134
7163460
Am J Clin Nutr. 1990 Jan;51(1):3-6
2296928
Support Care Cancer. 2001 Sep;9(6):408-19
11585267
Am J Clin Nutr. 1995 Feb;61(2):269-70
7840061
J Appl Physiol. 1969 Oct;27(4):531-4
4898406
Am J Clin Oncol. 1982 Dec;5(6):649-55
7165009
Kidney Int. 1998 Apr;53(4):1036-43
9551415
JAMA. 1999 Mar 17;281(11):1022-9
10086438
Ann N Y Acad Sci. 1999 Apr 20;873:105-11
10372157
Cochrane Database Syst Rev. 2014 Apr 23;(4):CD006273
24760678
J Pain Symptom Manage. 1995 Apr;10(3):192-7
7629413
J Pain Symptom Manage. 1993 Oct;8(7):454-64
7525778
Arch Gerontol Geriatr. 2010 May-Jun;50(3):e81-5
19616321
Int J Palliat Nurs. 2000 Sep;6(8):370-4
12411847
BMJ Support Palliat Care. 2016 Sep;6(3):369-72
27125269
Ann Hum Biol. 1988 May-Jun;15(3):237-40
3389733
Am J Hosp Palliat Care. 1994 Nov-Dec;11(6):22-7
7893564
J Palliat Med. 2013 Feb;16(2):185-9
23327196
J Am Soc Nephrol. 2005 Jan;16(1):151-61
15574506
Clin Nutr. 2004 Dec;23(6):1430-53
15556267
J Appl Physiol (1985). 1986 Apr;60(4):1327-32
3700310
J Appl Physiol (1985). 1988 Feb;64(2):529-34
3372410
Nutrition. 2000 Feb;16(2):120-4
10696635
Am J Hosp Palliat Care. 2007 Aug-Sep;24(4):264-9
17601836
Arch Phys Med Rehabil. 2003 Jan;84(1):58-61
12589621
Curr Opin Clin Nutr Metab Care. 2005 May;8(3):311-7
15809535
Pediatr Nephrol. 2010 Feb;25(2):329-34
19876654
Clin Nutr. 1999 Feb;18(1):35-9
10459080
J Palliat Care. 1997 Winter;13(4):23-7
9447808
Kidney Int. 1994 Aug;46(2):534-9
7967368
Semin Oncol Nurs. 1987 Nov;3(4):248-56
3423446
J Am Coll Nutr. 1992 Apr;11(2):199-209
1578098
Palliat Med. 2011 Jul;25(5):504-15
21708857
Ann Oncol. 2005 Apr;16(4):640-7
15684225
J Emerg Med. 1992 May-Jun;10(3):267-74
1624737
Int J Obes. 1991 Jan;15(1):17-25
2010255
Physiol Meas. 2004 Oct;25(5):1271-80
15535191
Physiol Behav. 1987;40(2):229-36
3306730
Lancet. 1993 Apr 24;341(8852):1049-51
8096957
J Pain Symptom Manage. 2006 Feb;31(2):130-9
16488346
J Physiol Pharmacol. 2012 Feb;63(1):101-4
22460467
Clin Nutr. 2004 Oct;23(5):1226-43
15380917
Miner Electrolyte Metab. 1996;22(1-3):76-8
8676831
Kidney Int. 2004 Sep;66(3):1266-71
15327426
Acta Diabetol. 2003 Oct;40 Suppl 1:S203-6
14618473
Hum Biol. 1987 Apr;59(2):299-309
3596569
Contrib Nephrol. 2010;164:143-152
20428000
Int J Obes Relat Metab Disord. 1998 Feb;22(2):97-104
9504317
J Pain Symptom Manage. 2013 Sep;46(3):433-446.e6
23200189
Am J Physiol. 1980 Nov;239(5):R476-82
7001928
Nutrition. 2002 Feb;18(2):153-67
11844647
Kidney Int. 2004 Mar;65(3):1050-63
14871426
BMJ. 2011 Aug 25;343:d4920
21868477
BMJ. 1994 May 14;308(6939):1271
8205020
Am J Clin Nutr. 1992 Nov;56(5):835-9
1415001